Luqa Pharmaceuticals to commercialize BMG Pharmas products in China & Hong Kong

Specifications:

Name:

Luqa Pharmaceuticals to commercialize BMG Pharmas products in China & Hong Kong

Location:

China and Hong Kong

Company:

Estimated Cost:

Source:

Luqa Pharmaceuticals to commercialize BMG Pharma’s products in China & Hong Kong BMG Pharma S.r.l and Luqa Pharmaceuticals are pleased to announce a long-term partnership for the commercialization of BMG’s products in China and Hong Kong. Under the terms of this agreement, Luqa will exclusively register and commercialize BMG’s highly innovative dermatology, oral care and Cancer Support Therapy products. The agreement will enable Luqa to rapidly expand its dermatology offering and enter the attractive oral care and supportive care market of China, fast growing and largely self-payment driven categories. The partnership covers IaluXid, a unique, non-antibiotic, combination gel formulation treating skin infections; GelX and GelX Xero, innovations in supportive care preventing and treating Oral Mucositis and Xerostomia; and Aftacure, treating aphthous ulcers and mouth lesions.. These products have been developed to address major unmet needs for patients and physicians in the evolving China market. Luqa expects to launch this family of products directly from late 2015 onwards. “We are pleased to enter into a partnership with Luqa Pharmaceuticals, a company with whom we share the vision and values. BMG’s proven innovation capabilities complements Luqa’s deep understanding of the evolving needs in China’s healthcare market”, said Marco Mastrodonato, President and CEO of BMG Pharma S.r.l. “This long-term partnership is a major milestone for BMG as it opens us the door to the most exciting healthcare market in the world.” “We are happy to have entered into this alliance with BMG Pharma S.r.l..”, said Robert Braithwaite, CEO of Luqa Pharmaceuticals. “We are excited to further expand into the fast growing and largely self pay areas of dermatology oral care and Cancer Support Therapy segments. This partnership with BMG is in line with our strategy to build a portfolio of innovative and high-growth potential products through targeted partnerships. BMG Pharma’s products complement our portfolio of innovative therapies, and we look forward to develop them into leading healthcare brands. We plan to work closely with BMG on a relationship that will contribute to the continued and sustainable growth of our company.” About Luqa Pharmaceuticals Luqa Pharmaceuticals is a China-based company that acquires, develops and commercializes innovative healthcare products suited to the needs of China. Luqa’s innovative product portfolio is designed to meet the needs of patients, healthcare institutions and physicians in the rapidly changing healthcare market of China. Luqa’s focus is on its products, identifying and investing in assets that will become leading and recognized brands in the therapeutic and channel niches they operate. About BMG Pharma S.r.l BMG Pharma S.r.l. is an Italian Specialty Pharmaceutical Company leveraging its proprietary technology to develop products that address unmet needs of patients. The Company is currently focused on cancer supportive care, dermatology, gynecology, ENT and oral health. BMG Pharma S.r.l. is dedicated to helping patients, pharmacists and physicians by providing valuable and innovative products to the market. http://www.luqapharma.com/luqa-pharmaceuticals-to-commercialize-bmg-pharmas-products-in-china-hong-kong/ Project Name Luqa Pharmaceuticals to commercialize BMG Pharmas products in China & Hong Kong Location China and Hong Kong Commence 2013 Completion 2015 Estimated Investment -NA- Capacity -NA- Key Players BMG Pharma S.r.l and Luqa Pharmaceuticals